Molecular Diagnostics Market by Product & Services (Reagents and Kits, Instruments, Software and Services), by Application (Genetic Tests, Infectious Diseases, Oncology, and Others), by Technology (PCR, INAAT, DNA Sequencing & NGS, In Situ Hybridization, DNA Microarrays, and Others), and by End-User (Diagnostic Laboratories, Hospitals, and Others)- Global Opportunity Analysis and Industry Forecast, 2019-2026; By Region (U.S., Canada, Mexico, Rest of North America, UK, France, Germany, Italy, Spain, Benelux Union, Nordic Countries , Rest of Europe, China, Japan, India, South Korea, Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia, Rest of Asia Pacific, Brazil, Argentina, Rest of Latin America, GCC countries, Southern Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Global Molecular Diagnostics Market was valued at US$ 8750.32 million in 2018 and is expected to reach US$ 16359.76 million by 2027, growing at an estimated CAGR of 7.2% over the forecast period.
Diagnostic testing is the cornerstone for an effective health care system and provides vital information so that health care providers and patients can make correct medical decisions. Nowadays, medical decision making is strongly based upon the diagnostics results. Diagnostics provide accurate, quantifiable metrics that guide each process level of health care such as identification, prevention, treatment and effective health management. Molecular diagnostics is a diverse and transforming diagnostic domain which leads to knowledge and insights for research and treatment in many diseases and disorders. Molecular diagnostics is termed as the identification of genomic variants, with the goal of promoting the identification, evaluation, sub-classification, prognosis, and control of therapy responses. Molecular diagnostics is the result of the lucrative interplay in the field of molecular genetics among laboratory medicine, genomics expertise, and technology, particularly with significant molecular genomic technology discoveries. It identifies and quantifies the presence of genetic material or proteins related to a specific health condition or illness, help to discover the biological mechanisms of the disease and allow clinicians to customize treatment at an individual level.
Molecular diagnostics detect DNA, RNA, and protein differences that shed light on whether a particular individual is predisposed to a disease, whether they currently have a disease, or whether a specific treatment choice is likely to be effective for a particular disease. These studies can also identify and measure the existence of different viruses, bacteria, or cell types so that doctor can recommend right antibiotic to combat the relevant infection. Molecular diagnostics are methods that propel ongoing research-level exploration of biomarkers (A biochemical molecule present in blood, other body fluids, or tissues which is an indication of a natural or irregular operation, or a disease or illness. A biomarker may be used to see how well the body is responding to an infection or disease care). Molecular diagnostics lead towards therapies developed around these biomarkers. The concept of molecular diagnostics plays an important role in ensuring that the new treatments are administered to the correct patients through a more accurate diagnosis of the exact nature of their specific condition. This has contributed to the emerging field of companion diagnostics, where a molecular diagnostic examination is used to assess whether a particular treatment (a medical accompaniment) is likely to be effective for an individual patient. Molecular diagnostic testing will help a woman realize the risk that her breast cancer will reoccur later in life, or tell a doctor which drug is the right treatment for a patient with late stage melanoma. Molecular diagnostics can recognize multiple strains of respiratory viruses in a single test, or monitor a patient's blood level of HIV virus to assess how well their treatment works.
Continuous technological innovation increases the speed and accuracy of molecular diagnostics, and a future in which full genome sequencing is regularly performed is not far away. Increasing automation allows advanced molecular processing to be carried out in the full range of healthcare environments, introducing state-of - the-art diagnostics to all parts of the globe. Therefore, technological advances in molecular diagnostics are expected to drive the molecular diagnostics market growth significantly, as they promote cost-effectiveness, precision, and portability.
SEGMENTAL ANALYSIS
The global molecular diagnostics market has been segmented on the basis of products and services, by application, by technology and by end user.
- By Products and Services: During the forecast period, molecular diagnostic reagents and kits are expected to grow at the fastest rate in molecular diagnostics market. Molecular Diagnostic Reagents are used to identify and measure viral and bacterial presences. Molecular reagent testing provides more accurate treatment of diseases. Manufacturers particularly concentrate on next-generation technology that will allow biologists to analyse and interpret the vast amount of genomic data. Technological advancements in the field of these reagents will include low-cost polymerase chain reaction equipment and fast identification of amplicons. One of the barriers to achieving personalized medicine was the introduction of laboratory procedures for the conducting and recording of complex molecular experiments. The rapidly changing research rosters and diverse systems for performing molecular diagnostics also ensured that many clinical labs still use labour-intensive manual sorting and monitoring without the level of automation seen in high-volume chemistry and haematology studies. These software and services offer Capture and analyse high volume genomic and proteomic data, ensure data integrity and security to meet regulatory requirements, enhance and simplify patient report preparation, Interface seamlessly with third party providers, insurers and physicians and also Integrate existing systems into a single user interface. Using software and services here resulted in improved turn-around time for reporting more complex molecular test sets, as well as major process improvements. Therefore, software and services have bright future and are attracting many key players to innovate and produce new software and services.
- By Application: In terms of application, the molecular diagnostics market has been split into genetic tests, infectious diseases, oncology and others. Over recent years, the use of molecular diagnostics has increased, and what once was a technique reserved for specialist centres is now in common use in most diagnostic labs. Comprehensive molecular diagnostics have now become a standard of even simple laboratories, treating diseases such as influenza, human immunodeficiency viruses, methicillin-resistant Staphylococcus aureus, including the ability to diagnose drug resistance. The key use remains in the world of virology, where molecular diagnostics have been able to replace long cultivation methods which allow safe and fast diagnosis. Genetic research aids in the discovery of genetic and chromosomal variations associated with disease and risk conditions. Molecular diagnostics consist of sophisticated laboratory tools in which genetic sequences, biomarkers, metabolites and other molecules are detected and analysed. The aim of these molecular diagnostic methods is to help patients and their doctors identify individuals with a genetic disposition to a particular disease, predict whether that person has a disease at an earlier stage of the disease, determine an individual's efficacy of a particular drug treatment and explain the exact nature of a disease or seriousness of the disease. Development of new tests, greater awareness of their applicability by doctors and patients, lower-cost testing and access in wider clinical environments are all expected to contribute to increased adoption of molecular diagnostics.Cancer is a genetic disease of somatic cells. The genetic experiments are used to determine a person's risk of future illness who may be stable at the time of the test. Molecular diagnostic tests are important in the cancer for determining familial cancer syndromes. The molecular approach allows early detection, accurate diagnosis and accelerated cancer treatment. The molecular methods have allowed the development of DNA microarray. That can be used in the diagnosis and therapeutic evaluation of disease for a thorough identification of many cancer-associated mutations or for gene profiles. Molecular diagnosis has developed many basic tools for early detection, accurate diagnosis and rapid cancer treatment. Different tumors can be accurately distinguished from each other through the use of molecular methods.
- By Techniques: DNA sequencing is a simple technique for quick results which can be set up directly in the clinic. Reasons like developments in sequencing technology and growing focus on the development and launch of diagnostics by key market players fuel the growth of DNA sequencing. NGS (next-generation sequencing) kits and panel’s growing awareness and acceptance of personalized medicine, and expanded use of molecular diagnostic techniques in pharmacogenetics, genomics science, and point-of-care testing are expected to fuel the development of this technology in the coming years.NGS techniques are used in full-genome sequencing, selective re-sequencing, and non-coding RNA expression profiling, as well as in the exploration of binding sites for transcription factors. Previously, university and government research centres used this technique mainly for genomics experiments; with advances in technology, it acts as a possible ground-breaking diagnostic tool in infectious disease and cancer studies. Advancement of technology and the falling prices of NGS-based tests also drive growth in this technology segment.
- By End User: Private laboratories are dominating in molecular diagnostics market. These labs receive samples from hospitals or research sites and they perform diagnostic operations. Many hospitals have integral labs in their premises and at distance as well. Independent laboratories now a days have advance sample collection tools, special testing capabilities and provide fast test results. Thus, growing their influence in Molecular Diagnostic market.
- By Geography: The largest share of molecular diagnostics market is held by North America and expected to reach greater heights. Developed healthcare and diagnostic sector along with technologically advanced instruments are aiding the growth of this market in this region. Europe also has notable share in this market because of high prevalence of infectious diseases and cancers, availability of government funds, easy accessibility to hospital boost the growth of molecular diagnostic market. The market in APAC has also made remarkable achievements and expected to grow due to rising disposable income, increased governmental spending on public healthcare, modernization of hospitals and clinics and penetration of new diagnostic technologies in rural areas.
The regulatory approval framework has always been a major restrictive factor with regard to medical products and medical technology industries. The regulatory environment is already complex, and because of the increasing emphasis on molecular diagnostics to make critical medical decisions, the FDA is becoming ever more vigilant. Therefore, the possibility of causing patients damage has caused the FDA to affirm compliance with pre-marketing legislation.
Global Molecular Diagnostics Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
Key players in the global molecular diagnostics market include Roche Diagnostics; Abbott; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Alere, Inc.; Bayer AG; Dako; Hologic, Inc. (Gen probe); Sysmex Corporation; Danaher; Johnson & Johnson; Novartis AG; Qiagen N.V.; Becton, Dickinson and Company; Cepheid; and bioMerieux SA.
Key players in molecular diagnostics market are adopting various strategies such as mergers and acquisitions to increase their market share. For instance, Qiagen acquired STAT-Dx, a Spanish firm developing next-generation multiplex diagnostics using a novel system based on real-time PCR and Qiagen chemistries. Players are also focusing on expanding their product portfolio. For instance, in 2019, Roche Diagnostics launched the first IVD ROS1 IHC assay-VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody-for the detection of ROS1 protein in cancers.
Molecular Diagnostics Healthcare Market:
- Products and Services
- Reagents and Kits
- Instruments
- Software and Services
- By Application
- Genetic Tests
- Infectious Diseases
- Oncology
- Others
- By Technology
- PCR
- INAAT
- DNA Sequencing & NGS
- In Situ Hybridization
- DNA Microarrays
- Others
- By End-user
- Diagnostic Laboratories
- Hospitals
- Others
- By Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Molecular Diagnostics Market
6. Market Synopsis:
Molecular Diagnostics Market
7. Molecular Diagnostics Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Molecular Diagnostics Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Molecular Diagnostics Market
7.6. Porter’s
Five Force Analysis
8. Global Molecular Diagnostics Market Analysis and Forecasts,
2019 – 2027
8.1. Overview
8.1.1. Global
Molecular Diagnostics Market Revenue (US$ Mn)
8.2. Global
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
8.2.1. Reagents
and Kits
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Instruments
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Software
and Services
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Products and Services
9. Global Molecular Diagnostics Market Analysis and Forecasts,
2019 – 2027
9.1. Overview
9.2. Global
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Genetic
Tests
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Infectious
Diseases
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Oncology
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Molecular Diagnostics Market Analysis and Forecasts,
2019 – 2027
10.1. Overview
10.2. Global
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
10.2.1. PCR
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. INAAT
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. DNA
Sequencing and NGS
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.2.4. In Situ
Hybridization
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2013 – 2018
10.2.4.3. Market
Forecast, 2019 – 2027
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2013 – 2018
10.2.4.5.1.2. Market
Forecast, 2019 – 2027
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2013 – 2018
10.2.4.5.2.2. Market
Forecast, 2019 – 2027
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2013 – 2018
10.2.4.5.3.2. Market
Forecast, 2019 – 2027
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2013 – 2018
10.2.4.5.4.2. Market
Forecast, 2019 – 2027
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2013 – 2018
10.2.4.5.5.2. Market
Forecast, 2019 – 2027
10.2.5. DNA
Microarrays
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2013 – 2018
10.2.5.3. Market
Forecast, 2019 – 2027
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2013 – 2018
10.2.5.5.1.2. Market
Forecast, 2019 – 2027
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2013 – 2018
10.2.5.5.2.2. Market
Forecast, 2019 – 2027
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2013 – 2018
10.2.5.5.3.2. Market
Forecast, 2019 – 2027
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2013 – 2018
10.2.5.5.4.2. Market
Forecast, 2019 – 2027
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2013 – 2018
10.2.5.5.5.2. Market
Forecast, 2019 – 2027
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2013 – 2018
10.2.6.3. Market
Forecast, 2019 – 2027
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2013 – 2018
10.2.6.5.1.2. Market
Forecast, 2019 – 2027
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2013 – 2018
10.2.6.5.2.2. Market
Forecast, 2019 – 2027
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2013 – 2018
10.2.6.5.3.2. Market
Forecast, 2019 – 2027
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2013 – 2018
10.2.6.5.4.2. Market
Forecast, 2019 – 2027
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2013 – 2018
10.2.6.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By
Technology
11. Global Molecular Diagnostics Market Analysis and Forecasts,
2019 – 2027
11.1. Overview
11.2. Global
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
11.2.1. Diagnostic
Laboratories
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2013 – 2018
11.2.1.3. Market
Forecast, 2019 – 2027
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2013 – 2018
11.2.1.5.1.2. Market
Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2013 – 2018
11.2.1.5.2.2. Market
Forecast, 2019 – 2027
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2013 – 2018
11.2.1.5.3.2. Market
Forecast, 2019 – 2027
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2013 – 2018
11.2.1.5.4.2. Market
Forecast, 2019 – 2027
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2013 – 2018
11.2.1.5.5.2. Market
Forecast, 2019 – 2027
11.2.2. Hospitals
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2013 – 2018
11.2.2.3. Market
Forecast, 2019 – 2027
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2013 – 2018
11.2.2.5.1.2. Market
Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2013 – 2018
11.2.2.5.2.2. Market
Forecast, 2019 – 2027
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2013 – 2018
11.2.2.5.3.2. Market
Forecast, 2019 – 2027
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2013 – 2018
11.2.2.5.4.2. Market
Forecast, 2019 – 2027
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2013 – 2018
11.2.2.5.5.2. Market
Forecast, 2019 – 2027
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2013 – 2018
11.2.3.3. Market
Forecast, 2019 – 2027
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2013 – 2018
11.2.3.5.1.2. Market
Forecast, 2019 – 2027
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2013 – 2018
11.2.3.5.2.2. Market
Forecast, 2019 – 2027
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2013 – 2018
11.2.3.5.3.2. Market
Forecast, 2019 – 2027
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2013 – 2018
11.2.3.5.4.2. Market
Forecast, 2019 – 2027
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2013 – 2018
11.2.3.5.5.2. Market
Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By
End-user
12. North America Molecular Diagnostics Market Analysis and
Forecasts, 2019 - 2027
12.1. Overview
12.1.1. North
America Molecular Diagnostics Market Revenue (US$ Mn)
12.2. North
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
12.2.1. Reagents
and Kits
12.2.2. Instruments
12.2.3. Software
and Services
12.3. North
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
12.3.1. Genetic
Tests
12.3.2. Infectious
Diseases
12.3.3. Oncology
12.3.4. Others
12.4. North
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
12.4.1. PCR
12.4.2. INAAT
12.4.3. DNA
Sequencing and NGS
12.4.4. In Situ
Hybridization
12.4.5. DNA
Microarrays
12.4.6. Others
12.5. North
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.1. Diagnostic
Laboratories
12.5.2. Hospitals
12.5.3. Others
12.6. North
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
12.6.1.1.1. Reagents
and Kits
12.6.1.1.2. Instruments
12.6.1.1.3. Software
and Services
12.6.1.2. U.S
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.2.1. Genetic
Tests
12.6.1.2.2. Infectious
Diseases
12.6.1.2.3. Oncology
12.6.1.2.4. Others
12.6.1.3. U.S
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.1.3.1. PCR
12.6.1.3.2. INAAT
12.6.1.3.3. DNA
Sequencing and NGS
12.6.1.3.4. In
Situ Hybridization
12.6.1.3.5. DNA
Microarrays
12.6.1.3.6. Others
12.6.1.4. U.S
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
12.6.1.4.1. Diagnostic
Laboratories
12.6.1.4.2. Hospitals
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
12.6.2.1.1. Reagents
and Kits
12.6.2.1.2. Instruments
12.6.2.1.3. Software
and Services
12.6.2.2. Canada
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.2.1. Genetic
Tests
12.6.2.2.2. Infectious
Diseases
12.6.2.2.3. Oncology
12.6.2.2.4. Others
12.6.2.3. Canada
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.2.3.1. PCR
12.6.2.3.2. INAAT
12.6.2.3.3. DNA
Sequencing and NGS
12.6.2.3.4. In
Situ Hybridization
12.6.2.3.5. DNA
Microarrays
12.6.2.3.6. Others
12.6.2.4. Canada
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
12.6.2.4.1. Diagnostic
Laboratories
12.6.2.4.2. Hospitals
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
12.6.3.1.1. Reagents
and Kits
12.6.3.1.2. Instruments
12.6.3.1.3. Software
and Services
12.6.3.2. Mexico
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.2.1. Genetic
Tests
12.6.3.2.2. Infectious
Diseases
12.6.3.2.3. Oncology
12.6.3.2.4. Others
12.6.3.3. Mexico
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.3.3.1. PCR
12.6.3.3.2. INAAT
12.6.3.3.3. DNA
Sequencing and NGS
12.6.3.3.4. In
Situ Hybridization
12.6.3.3.5. DNA
Microarrays
12.6.3.3.6. Others
12.6.3.4. Mexico
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
12.6.3.4.1. Diagnostic
Laboratories
12.6.3.4.2. Hospitals
12.6.3.4.3. Others
12.6.4. Rest of
North America
12.6.4.1. Rest
of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Products and Services
12.6.4.1.1. Reagents
and Kits
12.6.4.1.2. Instruments
12.6.4.1.3. Software
and Services
12.6.4.2. Rest
of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Application
12.6.4.2.1. Genetic
Tests
12.6.4.2.2. Infectious
Diseases
12.6.4.2.3. Oncology
12.6.4.2.4. Others
12.6.4.3. Rest
of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Technology
12.6.4.3.1. PCR
12.6.4.3.2. INAAT
12.6.4.3.3. DNA
Sequencing and NGS
12.6.4.3.4. In
Situ Hybridization
12.6.4.3.5. DNA
Microarrays
12.6.4.3.6. Others
12.6.4.4. Rest
of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By End-user
12.6.4.4.1. Diagnostic
Laboratories
12.6.4.4.2. Hospitals
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Products and Services
12.7.3. By
Application
12.7.4. By
Technology
12.7.5. By
End-user
13. Europe Molecular Diagnostics Market Analysis and Forecasts,
2019 - 2027
13.1. Overview
13.1.1. Europe
Molecular Diagnostics Market Revenue (US$ Mn)
13.2. Europe
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
13.2.1. Reagents
and Kits
13.2.2. Instruments
13.2.3. Software
and Services
13.3. Europe
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Genetic
Tests
13.3.2. Infectious
Diseases
13.3.3. Oncology
13.3.4. Others
13.4. Europe
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.4.1. PCR
13.4.2. INAAT
13.4.3. DNA
Sequencing and NGS
13.4.4. In Situ
Hybridization
13.4.5. DNA
Microarrays
13.4.6. Others
13.5. Europe
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.5.1. Diagnostic
Laboratories
13.5.2. Hospitals
13.5.3. Others
13.6. Europe
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
13.6.1.1.1. Reagents
and Kits
13.6.1.1.2. Instruments
13.6.1.1.3. Software
and Services
13.6.1.2. France
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.2.1. Genetic
Tests
13.6.1.2.2. Infectious
Diseases
13.6.1.2.3. Oncology
13.6.1.2.4. Others
13.6.1.3. France
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.1.3.1. PCR
13.6.1.3.2. INAAT
13.6.1.3.3. DNA
Sequencing and NGS
13.6.1.3.4. In
Situ Hybridization
13.6.1.3.5. DNA
Microarrays
13.6.1.3.6. Others
13.6.1.4. France
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.6.1.4.1. Diagnostic
Laboratories
13.6.1.4.2. Hospitals
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The
UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
13.6.2.1.1. Reagents
and Kits
13.6.2.1.2. Instruments
13.6.2.1.3. Software
and Services
13.6.2.2. The
UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.2.1. Genetic
Tests
13.6.2.2.2. Infectious
Diseases
13.6.2.2.3. Oncology
13.6.2.2.4. Others
13.6.2.3. The
UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.2.3.1. PCR
13.6.2.3.2. INAAT
13.6.2.3.3. DNA
Sequencing and NGS
13.6.2.3.4. In
Situ Hybridization
13.6.2.3.5. DNA
Microarrays
13.6.2.3.6. Others
13.6.2.4. The
UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.6.2.4.1. Diagnostic
Laboratories
13.6.2.4.2. Hospitals
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
13.6.3.1.1. Reagents
and Kits
13.6.3.1.2. Instruments
13.6.3.1.3. Software
and Services
13.6.3.2. Spain
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.2.1. Genetic
Tests
13.6.3.2.2. Infectious
Diseases
13.6.3.2.3. Oncology
13.6.3.2.4. Others
13.6.3.3. Spain
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.3.3.1. PCR
13.6.3.3.2. INAAT
13.6.3.3.3. DNA
Sequencing and NGS
13.6.3.3.4. In
Situ Hybridization
13.6.3.3.5. DNA
Microarrays
13.6.3.3.6. Others
13.6.3.4. Spain
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.6.3.4.1. Diagnostic
Laboratories
13.6.3.4.2. Hospitals
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
13.6.4.1.1. Reagents
and Kits
13.6.4.1.2. Instruments
13.6.4.1.3. Software
and Services
13.6.4.2. Germany
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.4.2.1. Genetic
Tests
13.6.4.2.2. Infectious
Diseases
13.6.4.2.3. Oncology
13.6.4.2.4. Others
13.6.4.3. Germany
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.4.3.1. PCR
13.6.4.3.2. INAAT
13.6.4.3.3. DNA
Sequencing and NGS
13.6.4.3.4. In
Situ Hybridization
13.6.4.3.5. DNA
Microarrays
13.6.4.3.6. Others
13.6.4.4. Germany
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.6.4.4.1. Diagnostic
Laboratories
13.6.4.4.2. Hospitals
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
13.6.5.1.1. Reagents
and Kits
13.6.5.1.2. Instruments
13.6.5.1.3. Software
and Services
13.6.5.2. Italy
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.2.1. Genetic
Tests
13.6.5.2.2. Infectious
Diseases
13.6.5.2.3. Oncology
13.6.5.2.4. Others
13.6.5.3. Italy
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.5.3.1. PCR
13.6.5.3.2. INAAT
13.6.5.3.3. DNA
Sequencing and NGS
13.6.5.3.4. In
Situ Hybridization
13.6.5.3.5. DNA
Microarrays
13.6.5.3.6. Others
13.6.5.4. Italy
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.6.5.4.1. Diagnostic
Laboratories
13.6.5.4.2. Hospitals
13.6.5.4.3. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic
Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
13.6.6.1.1. Reagents
and Kits
13.6.6.1.2. Instruments
13.6.6.1.3. Software
and Services
13.6.6.2. Nordic
Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.6.2.1. Genetic
Tests
13.6.6.2.2. Infectious
Diseases
13.6.6.2.3. Oncology
13.6.6.2.4. Others
13.6.6.3. Nordic
Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.6.3.1. PCR
13.6.6.3.2. INAAT
13.6.6.3.3. DNA
Sequencing and NGS
13.6.6.3.4. In
Situ Hybridization
13.6.6.3.5. DNA
Microarrays
13.6.6.3.6. Others
13.6.6.4. Nordic
Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
13.6.6.4.1. Diagnostic
Laboratories
13.6.6.4.2. Hospitals
13.6.6.4.3. Others
13.6.6.5. Nordic
Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux
Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
and Services
13.6.7.1.1. Reagents
and Kits
13.6.7.1.2. Instruments
13.6.7.1.3. Software
and Services
13.6.7.2. Benelux
Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.7.2.1. Genetic
Tests
13.6.7.2.2. Infectious
Diseases
13.6.7.2.3. Oncology
13.6.7.2.4. Others
13.6.7.3. Benelux
Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.7.3.1. PCR
13.6.7.3.2. INAAT
13.6.7.3.3. DNA
Sequencing and NGS
13.6.7.3.4. In
Situ Hybridization
13.6.7.3.5. DNA
Microarrays
13.6.7.3.6. Others
13.6.7.4. Benelux
Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
13.6.7.4.1. Diagnostic
Laboratories
13.6.7.4.2. Hospitals
13.6.7.4.3. Others
13.6.7.5. Benelux
Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest
of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
13.6.8.1.1. Reagents
and Kits
13.6.8.1.2. Instruments
13.6.8.1.3. Software
and Services
13.6.8.2. Rest
of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.8.2.1. Genetic
Tests
13.6.8.2.2. Infectious
Diseases
13.6.8.2.3. Oncology
13.6.8.2.4. Others
13.6.8.3. Rest
of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
13.6.8.3.1. PCR
13.6.8.3.2. INAAT
13.6.8.3.3. DNA
Sequencing and NGS
13.6.8.3.4. In
Situ Hybridization
13.6.8.3.5. DNA
Microarrays
13.6.8.3.6. Others
13.6.8.4. Rest
of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
13.6.8.4.1. Diagnostic
Laboratories
13.6.8.4.2. Hospitals
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Products and Services
13.7.3. By
Application
13.7.4. By
Technology
13.7.5. By
End-user
14. Asia Pacific Molecular Diagnostics Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Asia
Pacific Molecular Diagnostics Market Revenue (US$ Mn)
14.2. Asia
Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
14.2.1. Reagents
and Kits
14.2.2. Instruments
14.2.3. Software
and Services
14.3. Asia
Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Genetic
Tests
14.3.2. Infectious
Diseases
14.3.3. Oncology
14.3.4. Others
14.4. Asia
Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
14.4.1. PCR
14.4.2. INAAT
14.4.3. DNA
Sequencing and NGS
14.4.4. In Situ
Hybridization
14.4.5. DNA
Microarrays
14.4.6. Others
14.5. Asia
Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
14.5.1. Diagnostic
Laboratories
14.5.2. Hospitals
14.5.3. Others
14.6. Asia
Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
14.6.1.1.1. Reagents
and Kits
14.6.1.1.2. Instruments
14.6.1.1.3. Software
and Services
14.6.1.2. China
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.2.1. Genetic
Tests
14.6.1.2.2. Infectious
Diseases
14.6.1.2.3. Oncology
14.6.1.2.4. Others
14.6.1.3. China
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.1.3.1. PCR
14.6.1.3.2. INAAT
14.6.1.3.3. DNA
Sequencing and NGS
14.6.1.3.4. In
Situ Hybridization
14.6.1.3.5. DNA
Microarrays
14.6.1.3.6. Others
14.6.1.4. China
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
14.6.1.4.1. Diagnostic
Laboratories
14.6.1.4.2. Hospitals
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
14.6.2.1.1. Reagents
and Kits
14.6.2.1.2. Instruments
14.6.2.1.3. Software
and Services
14.6.2.2. Japan
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.2.1. Genetic
Tests
14.6.2.2.2. Infectious
Diseases
14.6.2.2.3. Oncology
14.6.2.2.4. Others
14.6.2.3. Japan
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.2.3.1. PCR
14.6.2.3.2. INAAT
14.6.2.3.3. DNA
Sequencing and NGS
14.6.2.3.4. In
Situ Hybridization
14.6.2.3.5. DNA
Microarrays
14.6.2.3.6. Others
14.6.2.4. Japan
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
14.6.2.4.1. Diagnostic
Laboratories
14.6.2.4.2. Hospitals
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
14.6.3.1.1. Reagents
and Kits
14.6.3.1.2. Instruments
14.6.3.1.3. Software
and Services
14.6.3.2. India
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.2.1. Genetic
Tests
14.6.3.2.2. Infectious
Diseases
14.6.3.2.3. Oncology
14.6.3.2.4. Others
14.6.3.3. India
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.3.3.1. PCR
14.6.3.3.2. INAAT
14.6.3.3.3. DNA
Sequencing and NGS
14.6.3.3.4. In
Situ Hybridization
14.6.3.3.5. DNA
Microarrays
14.6.3.3.6. Others
14.6.3.4. India
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
14.6.3.4.1. Diagnostic
Laboratories
14.6.3.4.2. Hospitals
14.6.3.4.3. Others
14.6.4. New
Zealand
14.6.4.1. New
Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
14.6.4.1.1. Reagents
and Kits
14.6.4.1.2. Instruments
14.6.4.1.3. Software
and Services
14.6.4.2. New
Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.4.2.1. Genetic
Tests
14.6.4.2.2. Infectious
Diseases
14.6.4.2.3. Oncology
14.6.4.2.4. Others
14.6.4.3. New
Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.4.3.1. PCR
14.6.4.3.2. INAAT
14.6.4.3.3. DNA
Sequencing and NGS
14.6.4.3.4. In
Situ Hybridization
14.6.4.3.5. DNA
Microarrays
14.6.4.3.6. Others
14.6.4.4. New
Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
14.6.4.4.1. Diagnostic
Laboratories
14.6.4.4.2. Hospitals
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
14.6.5.1.1. Reagents
and Kits
14.6.5.1.2. Instruments
14.6.5.1.3. Software
and Services
14.6.5.2. Australia
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.5.2.1. Genetic
Tests
14.6.5.2.2. Infectious
Diseases
14.6.5.2.3. Oncology
14.6.5.2.4. Others
14.6.5.3. Australia
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.5.3.1. PCR
14.6.5.3.2. INAAT
14.6.5.3.3. DNA
Sequencing and NGS
14.6.5.3.4. In
Situ Hybridization
14.6.5.3.5. DNA
Microarrays
14.6.5.3.6. Others
14.6.5.4. Australia
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
14.6.5.4.1. Diagnostic
Laboratories
14.6.5.4.2. Hospitals
14.6.5.4.3. Others
14.6.6. South
Korea
14.6.6.1. South
Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
and Services
14.6.6.1.1. Reagents
and Kits
14.6.6.1.2. Instruments
14.6.6.1.3. Software
and Services
14.6.6.2. South
Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.6.2.1. Genetic
Tests
14.6.6.2.2. Infectious
Diseases
14.6.6.2.3. Oncology
14.6.6.2.4. Others
14.6.6.3. South
Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.6.3.1. PCR
14.6.6.3.2. INAAT
14.6.6.3.3. DNA
Sequencing and NGS
14.6.6.3.4. In
Situ Hybridization
14.6.6.3.5. DNA
Microarrays
14.6.6.3.6. Others
14.6.6.4. South
Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
14.6.6.4.1. Diagnostic
Laboratories
14.6.6.4.2. Hospitals
14.6.6.4.3. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast
Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
and Services
14.6.7.1.1. Reagents
and Kits
14.6.7.1.2. Instruments
14.6.7.1.3. Software
and Services
14.6.7.2. Southeast
Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.7.2.1. Genetic
Tests
14.6.7.2.2. Infectious
Diseases
14.6.7.2.3. Oncology
14.6.7.2.4. Others
14.6.7.3. Southeast
Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.7.3.1. PCR
14.6.7.3.2. INAAT
14.6.7.3.3. DNA
Sequencing and NGS
14.6.7.3.4. In
Situ Hybridization
14.6.7.3.5. DNA
Microarrays
14.6.7.3.6. Others
14.6.7.4. Southeast
Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
14.6.7.4.1. Diagnostic
Laboratories
14.6.7.4.2. Hospitals
14.6.7.4.3. Others
14.6.7.5. Southeast
Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest
of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest
of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
14.6.8.1.1. Reagents
and Kits
14.6.8.1.2. Instruments
14.6.8.1.3. Software
and Services
14.6.8.2. Rest
of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.8.2.1. Genetic
Tests
14.6.8.2.2. Infectious
Diseases
14.6.8.2.3. Oncology
14.6.8.2.4. Others
14.6.8.3. Rest
of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
14.6.8.3.1. PCR
14.6.8.3.2. INAAT
14.6.8.3.3. DNA
Sequencing and NGS
14.6.8.3.4. In
Situ Hybridization
14.6.8.3.5. DNA
Microarrays
14.6.8.3.6. Others
14.6.8.4. Rest
of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
14.6.8.4.1. Diagnostic
Laboratories
14.6.8.4.2. Hospitals
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Products and Services
14.7.3. By
Application
14.7.4. By Technology
14.7.5. By
End-user
15. Middle East and Africa Molecular Diagnostics Market Analysis
and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Middle
East and Africa Molecular Diagnostics Market Revenue (US$ Mn)
15.2. Middle
East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
15.2.1. Reagents
and Kits
15.2.2. Instruments
15.2.3. Software
and Services
15.3. Middle
East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
15.3.1. Genetic
Tests
15.3.2. Infectious
Diseases
15.3.3. Oncology
15.3.4. Others
15.4. Middle
East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
15.4.1. PCR
15.4.2. INAAT
15.4.3. DNA
Sequencing and NGS
15.4.4. In Situ
Hybridization
15.4.5. DNA
Microarrays
15.4.6. Others
15.5. Middle
East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
15.5.1. Diagnostic
Laboratories
15.5.2. Hospitals
15.5.3. Others
15.6. Middle
East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi
Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
and Services
15.6.1.1.1. Reagents
and Kits
15.6.1.1.2. Instruments
15.6.1.1.3. Software
and Services
15.6.1.2. Saudi
Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.1.2.1. Genetic
Tests
15.6.1.2.2. Infectious
Diseases
15.6.1.2.3. Oncology
15.6.1.2.4. Others
15.6.1.3. Saudi
Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
15.6.1.3.1. PCR
15.6.1.3.2. INAAT
15.6.1.3.3. DNA
Sequencing and NGS
15.6.1.3.4. In
Situ Hybridization
15.6.1.3.5. DNA
Microarrays
15.6.1.3.6. Others
15.6.1.4. Saudi
Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
15.6.1.4.1. Diagnostic
Laboratories
15.6.1.4.2. Hospitals
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
15.6.2.1.1. Reagents
and Kits
15.6.2.1.2. Instruments
15.6.2.1.3. Software
and Services
15.6.2.2. UAE
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.2.1. Genetic
Tests
15.6.2.2.2. Infectious
Diseases
15.6.2.2.3. Oncology
15.6.2.2.4. Others
15.6.2.3. UAE
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.2.3.1. PCR
15.6.2.3.2. INAAT
15.6.2.3.3. DNA
Sequencing and NGS
15.6.2.3.4. In
Situ Hybridization
15.6.2.3.5. DNA
Microarrays
15.6.2.3.6. Others
15.6.2.4. UAE
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
15.6.2.4.1. Diagnostic
Laboratories
15.6.2.4.2. Hospitals
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
15.6.3.1.1. Reagents
and Kits
15.6.3.1.2. Instruments
15.6.3.1.3. Software
and Services
15.6.3.2. Egypt
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.2.1. Genetic
Tests
15.6.3.2.2. Infectious
Diseases
15.6.3.2.3. Oncology
15.6.3.2.4. Others
15.6.3.3. Egypt
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.3.3.1. PCR
15.6.3.3.2. INAAT
15.6.3.3.3. DNA
Sequencing and NGS
15.6.3.3.4. In
Situ Hybridization
15.6.3.3.5. DNA
Microarrays
15.6.3.3.6. Others
15.6.3.4. Egypt
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
15.6.3.4.1. Diagnostic
Laboratories
15.6.3.4.2. Hospitals
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
15.6.4.1.1. Reagents
and Kits
15.6.4.1.2. Instruments
15.6.4.1.3. Software
and Services
15.6.4.2. Kuwait
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.2.1. Genetic
Tests
15.6.4.2.2. Infectious
Diseases
15.6.4.2.3. Oncology
15.6.4.2.4. Others
15.6.4.3. Kuwait
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.4.3.1. PCR
15.6.4.3.2. INAAT
15.6.4.3.3. DNA
Sequencing and NGS
15.6.4.3.4. In
Situ Hybridization
15.6.4.3.5. DNA
Microarrays
15.6.4.3.6. Others
15.6.4.4. Kuwait
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
15.6.4.4.1. Diagnostic
Laboratories
15.6.4.4.2. Hospitals
15.6.4.4.3. Others
15.6.5. South
Africa
15.6.5.1. South
Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products
and Services
15.6.5.1.1. Reagents
and Kits
15.6.5.1.2. Instruments
15.6.5.1.3. Software
and Services
15.6.5.2. South
Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.5.2.1. Genetic
Tests
15.6.5.2.2. Infectious
Diseases
15.6.5.2.3. Oncology
15.6.5.2.4. Others
15.6.5.3. South
Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
15.6.5.3.1. PCR
15.6.5.3.2. INAAT
15.6.5.3.3. DNA
Sequencing and NGS
15.6.5.3.4. In
Situ Hybridization
15.6.5.3.5. DNA
Microarrays
15.6.5.3.6. Others
15.6.5.4. South
Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
15.6.5.4.1. Diagnostic
Laboratories
15.6.5.4.2. Hospitals
15.6.5.4.3. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest
of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Products and Services
15.6.6.1.1. Reagents
and Kits
15.6.6.1.2. Instruments
15.6.6.1.3. Software
and Services
15.6.6.2. Rest
of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.6.2.1. Genetic
Tests
15.6.6.2.2. Infectious
Diseases
15.6.6.2.3. Oncology
15.6.6.2.4. Others
15.6.6.3. Rest
of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and
Forecasts, By Technology
15.6.6.3.1. PCR
15.6.6.3.2. INAAT
15.6.6.3.3. DNA
Sequencing and NGS
15.6.6.3.4. In
Situ Hybridization
15.6.6.3.5. DNA
Microarrays
15.6.6.3.6. Others
15.6.6.4. Rest
of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and
Forecasts, By End-user
15.6.6.4.1. Diagnostic
Laboratories
15.6.6.4.2. Hospitals
15.6.6.4.3. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By Products
and Services
15.7.3. By
Application
15.7.4. By
Technology
15.7.5. By
End-user
16. Latin America Molecular Diagnostics Market Analysis and
Forecasts, 2019 - 2027
16.1. Overview
16.1.1. Latin
America Molecular Diagnostics Market Revenue (US$ Mn)
16.2. Latin
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Products and Services
16.2.1. Reagents
and Kits
16.2.2. Instruments
16.2.3. Software
and Services
16.3. Latin
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Application
16.3.1. Genetic
Tests
16.3.2. Infectious
Diseases
16.3.3. Oncology
16.3.4. Others
16.4. Latin
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
Technology
16.4.1. PCR
16.4.2. INAAT
16.4.3. DNA
Sequencing and NGS
16.4.4. In Situ
Hybridization
16.4.5. DNA
Microarrays
16.4.6. Others
16.5. Latin
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By
End-user
16.5.1. Diagnostic
Laboratories
16.5.2. Hospitals
16.5.3. Others
16.6. Latin
America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
16.6.1.1.1. Reagents
and Kits
16.6.1.1.2. Instruments
16.6.1.1.3. Software
and Services
16.6.1.2. Brazil
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.2.1. Genetic
Tests
16.6.1.2.2. Infectious
Diseases
16.6.1.2.3. Oncology
16.6.1.2.4. Others
16.6.1.3. Brazil
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
16.6.1.3.1. PCR
16.6.1.3.2. INAAT
16.6.1.3.3. DNA
Sequencing and NGS
16.6.1.3.4. In
Situ Hybridization
16.6.1.3.5. DNA
Microarrays
16.6.1.3.6. Others
16.6.1.4. Brazil
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
16.6.1.4.1. Diagnostic
Laboratories
16.6.1.4.2. Hospitals
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Products and
Services
16.6.2.1.1. Reagents
and Kits
16.6.2.1.2. Instruments
16.6.2.1.3. Software
and Services
16.6.2.2. Argentina
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
16.6.2.2.1. Genetic
Tests
16.6.2.2.2. Infectious
Diseases
16.6.2.2.3. Oncology
16.6.2.2.4. Others
16.6.2.3. Argentina
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
16.6.2.3.1. PCR
16.6.2.3.2. INAAT
16.6.2.3.3. DNA
Sequencing and NGS
16.6.2.3.4. In
Situ Hybridization
16.6.2.3.5. DNA
Microarrays
16.6.2.3.6. Others
16.6.2.4. Argentina
Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End-user
16.6.2.4.1. Diagnostic
Laboratories
16.6.2.4.2. Hospitals
16.6.2.4.3. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest
of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Products and Services
16.6.3.1.1. Reagents
and Kits
16.6.3.1.2. Instruments
16.6.3.1.3. Software
and Services
16.6.3.2. Rest
of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Application
16.6.3.2.1. Genetic
Tests
16.6.3.2.2. Infectious
Diseases
16.6.3.2.3. Oncology
16.6.3.2.4. Others
16.6.3.3. Rest
of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By Technology
16.6.3.3.1. PCR
16.6.3.3.2. INAAT
16.6.3.3.3. DNA
Sequencing and NGS
16.6.3.3.4. In
Situ Hybridization
16.6.3.3.5. DNA
Microarrays
16.6.3.3.6. Others
16.6.3.4. Rest
of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts,
By End-user
16.6.3.4.1. Diagnostic
Laboratories
16.6.3.4.2. Hospitals
16.6.3.4.3. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Products and Services
16.7.3. By Application
16.7.4. By
Technology
16.7.5. By
End-user
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2018
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Abbott
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Alere,
Inc.
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. Bayer AG
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Bio Rad
Laboratories Inc.
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. bioMerieux
SA
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Cepheid
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Dako
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Danaher
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Hologic,
Inc.
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Novartis
AG
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT Analysis
18.10.7. Business
Strategies
18.11. Qiagen
N.V.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Siemens
Healthcare GmbH
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Sysmex
Corporation
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.